CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
CO33: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Adjuvant Palbociclib for ER+ Breast Cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A Preplanned Analysis of the Stage IIA Cohort
HN9 trial, a Randomized Phase II Study Of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed By Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed By Adjuvant Tremelimumab And Durvalumab In Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC), was closed to accrual with 121 of the planned 180 patients randomized.
CCTG BLC5 MAIN-CAV: Phase III Randomized Clinical Trial
The CCTG BLC5 MAIN-CAV international trial is now open in Canada testing the addition of a targeted anti-cancer drug to the usual immunotherapy treatment, in patients with metastatic urothelial cancer (mUC).This trial will test whether the addition of the anti-cancer drug, to the maintenance immunotherapy will or will not improve the patient’s overall survival.
